Rigel Pharmaceuticals Inc. (RIGL) News Headlines

▮ More

Date

Headline

6/8/2022 7:16:17 AM Why Rigel Pharma Stock Falling In Pre-market?

6/8/2022 7:02:44 AM Rigel Says FORWARD Phase 3 Trial Of Fostamatinib Did Not Demonstrate Statistical Significance In Primary Endpoint

5/24/2022 8:27:17 AM Knight Therapeutics Enters License And Supply Deals With Rigel Pharma To Commercialize Fostamatinib In Latin America

5/4/2022 5:35:51 AM ATRC Sees 16-20% Revenue Growth, RIGL On Watch, LUNG Breathes Easy, BPMC Braces For Busy Year

5/3/2022 4:04:33 PM Rigel Pharma Q1 Loss/share $0.16 Vs. Profit $0.22 Year Ago

5/3/2022 4:03:29 PM Rigel Pharmaceuticals Inc. Q1 Earnings Summary

5/3/2022 3:00:20 PM Rigel Pharmaceuticals Q1 22 Earnings Conference Call At 4:30 PM ET

4/8/2022 7:32:06 AM Rigel Announces Grant Of Stock Options To Purchase Aggregate Of 626,000 Shares To 15 Newly Hired Employees

3/8/2022 9:44:29 AM Rigel : Phase 2 Study Of Fostamatinib Shows Clinically Meaningful Hemoglobin Responses

3/8/2022 8:14:42 AM Rigel : Data From Phase 2 Study Of Fostamatinib For Warm Antibody Autoimmune Hemolytic Anemia Treatment Published

3/1/2022 4:06:59 PM Rigel Pharma Q4 Loss/share $0.13 Vs. Loss $0.11 Year Ago

3/1/2022 4:03:23 PM Rigel Pharmaceuticals Inc. Q4 loss increases in line with estimates

3/1/2022 2:00:24 PM Rigel Pharmaceuticals Q4 21 Earnings Conference Call At 4:30 PM ET

1/10/2022 8:43:47 AM Rigel Pharma Expects To Report Total Revenue Of Approximately $20.4 Mln In Q4

1/7/2022 8:03:54 PM Rigel Pharmaceuticals Announces Inducement Grants

12/21/2021 8:55:59 AM Rigel Pharma Says Fostamatinib Met Primary Endpoint In Phase 3 Trial In Japan - Quick Facts

12/21/2021 8:32:56 AM Rigel: Fostamatinib Meets Primary Endpoint In Phase 3 Trial In Japan For Chronic Immune Thrombocytopenia

12/16/2021 9:05:11 AM Rigel Appoints Kamil Ali-Jackson To Board

11/22/2021 7:37:35 AM Pre-market Movers: ASTR, VG, CEI, CMBM, PTNR…

11/15/2021 8:51:04 AM Rigel Pharma To Exit Early-stage Research; To Cut Workforce - Quick Facts